StudyFinder

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

432 Study Matches

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN) (I CAN)

To evaluate the efficacy of ravulizumab compared with placebo to reduce proteinuria in adult participants with IgAN

Principal Investigator: Sahar Koubar
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00021814
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• Immunoglobulin A Nephropathy (IgAN) diagnosis established on kidney biopsy
• stable and maximum allowed or tolerated RASI (ACEI and/or ARB) dose for ≥ 3 months prior to starting the study
• if receiving SGLT2I, DEARA, MRA or ERA must be on a stable and maximum allowed or tolerated dose for ≥ 3 months prior to starting the study
• see link to clinicaltrials.gov for complete Inclusion criteria
Exclusion Criteria:

• diagnosis of rapid progressive glomerulonephritis
• clinically significant renal disease other than IgAN
• uncontrolled diabetes mellitus with glycosylated hemoglobin (HbA1c) > 8.5%
• history of kidney transplant or planned kidney transplant
• see link to clinicaltrials.gov for complete Exclusion criteria
Conditions: Kidney, Prostate & Urinary
Keywords: Clinics and Surgery Center (CSC), iga Nephropathy, igan, Immunoglobulin A Nephropathy

A Randomized, Controlled, Multicenter, Phase 3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician s Choice in Patients with Advanced Melanoma That Has Progressed on an Anti-PD-1 and an Anti-CTLA-4 Containing Treatment Regimen [IGNYTE-3]

The purpose of this research is to compare the effects of nivolumab with vusolimogene oderparepvec (VO) against standard of care treatment drug(s) currently available for patients with advanced melanoma. We expect that taking part in this research will last up to 60 months.

Principal Investigator: Benjamin Manning
Age Group: Not specified
This study is NOT accepting healthy volunteers
IRB Number: STUDY00023233
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• at least 12 years old
• confirmed metastatic Stage IIIb through IV/M1a through M1d cutaneous melanoma that cannot be surgically removed
• disease progression (PD) on an approved anti-PD-1 and an anti-CTLA-4 treatment, administered either as a combination regimen (eg, nivolumab + ipilimumab) or in sequence for at least 8 weeks
• documented BRAF V600 mutation status
• see link to clinicaltrials.gov for complete inclusion criteria
Exclusion Criteria:

• more than 2 lines of systemic therapy for advanced melanoma
• known acute or chronic hepatitis
• known human immunodeficiency virus (HIV) infection
• prior cancer in the previous 3 years, except for locally curable cancers that have apparently been cured
• see link to clinicaltrials.gov for complete exclusion criteria
Conditions: Cancer
Keywords: Clinics and Surgery Center (CSC), Advanced Melanoma, Melanoma
I'm interested
Share via email
See this study on ClinicalTrials.gov

Tic Clips

This study is about learning more about the full range of what tics can look like. Participating includes filling out surveys and submitting two brief videos of yourself. We know tics can be really different across people. By getting a lot of videos of people doing tics, we hope to better understand the variety of tics that exist.

Principal Investigator: Christine Conelea
Age Group: Not specified
This study is NOT accepting healthy volunteers
IRB Number: STUDY00022426
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• Aged 4 years or older
• Self-report having tics
• Adult participant or parent is able to read in English
• Access to an internet connected device with video recording capability
Conditions: Brain & Nervous System, Children's Health
Keywords: CBIT, Motor tics, Tic Disorder, Tourette's syndrome, Vocal tics
I'm interested
Share via email

Standardized Microbiota Transplant Therapy in Crohn's Disease

The goal of this study is to determine if healthy donor microbes released in the small intestine act the same way as healthy donor microbes released in the large intestine for people with Crohn's Disease. We will see what good bacteria are present in intestinal biopsies at 8 weeks and look for improvement in inflammation with colonoscopy.

Principal Investigator: Byron Vaughn
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00023114
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 18 to 89 years old
• English speaking
• Diagnosis of Crohn's Disease (CD)
• currently experiencing a flare (Study will enroll people through 2027)
• Current CD therapies are in the maintenance phase of dosing
• Women who could become pregnant must remain abstinent or use a highly effective form of birth control (e.g., oral contraception, transdermal patch, barrier, intrauterine device)
• See link to clinicaltrials.gov for complete inclusion and exclusion criteria
Exclusion Criteria:

• Extensive bowel resection or ileostomy or colostomy
• Diagnosis of ulcerative colitis
• Women who are pregnant or breastfeeding
• History of anaphylactic food allergies
Conditions: Digestive & Liver Health
Keywords: Clinics and Surgery Center (CSC), Crohn's Disease, Fecal Microbiota, Gut bacteria, CD
I'm interested
Share via email
See this study on ClinicalTrials.gov

Neuroplasticity in REM Sleep Behavior Disorder

REM sleep behavior disorder (RBD) is a condition in which people physically act out their dreams while sleeping. Some people with RBD may later develop neurological conditions such as Parkinson's disease or related disorders. This study will examine changes in the brain over a two-year period using advanced brain imaging (7T MRI) and other neurological tests. Researchers will compare people with RBD to people without the disorder to better understand how the brain changes over time and identify potential early signs of neurological disease.

Principal Investigator: Colum MacKinnon
Age Group: 18 years and over
This study is also accepting healthy volunteers
IRB Number: STUDY00016232
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is also accepting healthy volunteers
Inclusion Criteria:

• aged 21-75
• diagnosed with REM Sleep Behavior Disorder (RBD)
Conditions: Brain & Nervous System
Keywords: aging, RBD, REM Sleep Behavior Disorder
I'm interested
Share via email

Development of Tobacco Related Biomarkers

To maintain a biorepository (sample bank) of biological samples from different tobacco users and non-users to investigate how tobacco and nicotine products affect our bodies. The samples will be used by researchers to develop methods to look for biological “markers” (biomarkers), or chemical changes in the body, that occur due to tobacco or nicotine exposure. The goal is to eventually use these biomarkers to improve detection, prevention, and treatment strategies for tobacco-related diseases.

Principal Investigator: Stephen Hecht, PhD
Age Group: 18 years and over
This study is also accepting healthy volunteers
IRB Number: STUDY00021394
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is also accepting healthy volunteers
Inclusion Criteria:
This study is currently recruiting healthy people who fit the following:
• formerly smoked cigarettes daily
• quit smoking in the last 2-10 years OR
• never used any tobacco products
Exclusion Criteria:

• younger than 21 years old
• unstable health condition
• use other tobacco products
Conditions: Community Health, Prevention & Wellness
Keywords: biomarkers, cigarettes, nicotine, smokeless tobacco, tobacco, former smoker, previous smoker, quit smoking
I'm interested
Share via email

Prefrontal Cortical Stimulation in Severe Treatment Resistant Depression

This study looks at the use of an implanted brain stimulator for people who have treatment resistant depression. The change in brain function by EEG and symptoms of depression will be examined. This study is open to people 22-70 years old with Medicare or Medicare Advantage insurance.

Principal Investigator: Ziad Nahas
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00006945
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• ages 22-55
• diagnosis of chronic (greater than or equal to 2 years) depression
• poor response to three or more antidepressant medications (staff will review)
• had or refused ECT therapy
• under the regular care of a psychiatrist
• enrolled in a Medicare program
• have at least two people over 22 years of age and live within 30 minutes of participants residence who could respond to study staff if needed
• able to have a MRI scan
Exclusion Criteria:

• actively suicidal or have a history of an attempt within the last year
• have a history of another major mental health diagnosis
• have a positive drug test
• have an implanted brain device
• pregnant
• history of seizures
Conditions: Mental Health & Addiction
Keywords: Clinics and Surgery Center (CSC), Chronic Depression, Depression
I'm interested
Share via email
See this study on ClinicalTrials.gov

Characterizing Neuropathic Pain in Individuals Receiving Inpatient Treatment for an Alcohol Use Disorder

This study aims to learn more about neurological symptoms associated with alcohol use. The study team plans to characterize neuropathic pain in individuals receiving in-patient treatment for alcohol use compared with moderate drinkers of the same age.

Principal Investigator: Jeff Boissoneault
Age Group: 18 years and over
IRB Number: STUDY00025425
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
Inclusion Criteria:

• between 21 and 65 years of age
• must speak English
• Moderate drinkers group: Use alcohol at least 2-4 times per month
• Treatment group: patients in the Fairview Lodging Program primarily seeking treatment for alcohol - use of nicotine, cannabis, cocaine, and hallucinogens are permissible
Conditions: Brain & Nervous System, Mental Health & Addiction
Keywords: alcohol use, Pain, sensation
I'm interested
Share via email

Department of Neurology Movement Disorders Research Registry

The purpose of the University of Minnesota (UMN) movement disorders research registry is to connect individuals interested in participating in Movement Disorders research with researchers at the University of Minnesota. The registry will allow individuals from the community to share their contact information, basic information about their health diagnoses, and research studies they participate in. This information will be stored for future research contact and be used to determine which movement disorders studies (if any) that an individual may qualify for. Click 'Visit the Study Website' to learn more and to sign up for the registry.

Principal Investigator: Paul Tuite
Age Group: 18 years and over
This study is also accepting healthy volunteers
IRB Number: STUDY00027303
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is also accepting healthy volunteers
Inclusion Criteria:

• interested in participating in movement disorders research at UMN
Conditions: Brain & Nervous System
Keywords: Dystonia, movement disorders, Parkinson's, Tremor
Visit study website
I'm interested
Share via email

Assessment of usability and satisfaction with a take-home device presenting sound and body stimulation for back pain

The purpose of this study is to measure the compliance, usability, and satisfaction of an at-home, multi-modal stimulation device in a diverse population of people with chronic lower back pain (cLBP) compared to a group of participants who are engaging in integrative health practices. The multi-modal device will include a combination of electrical stimulation, auditory stimulation, and integrative-health techniques, including mindfulness breathing, health coaching, and reflective journaling. The multi-modal device creation is based on prior knowledge in lower back pain treatment, which includes electrical stimulation of the back (Transcutaneous Electrical Nerve Stimulator or TENS) and integrative health modalities. Findings from this usability pilot study could help refine the approach and the multi-modal device for a future intervention study in cLBP participants.

Principal Investigator: Hubert Lim
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00021883
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• must have chronic lower back pain, defined as back pain lasting 3 or more months,
• willing to travel to the University of Minnesota and commit to the study duration
Exclusion Criteria:

• cannot have any implanted stimulation devices
Conditions: Bone, Joint & Muscle
Keywords: aging, Back Pain
I'm interested
Share via email

Improving Barriers to Care Access for Children with Autism and Related Needs via Telehealth for Evaluation, Care Navigating, and Caregiver Coaching

Researchers at the University of Minnesota, Twin Cities are looking for research participants for a study about the efficacy of early intervention services provided over telehealth (video conferencing) for kids ages 1-5 years old with Autism Spectrum Disorder (ASD) and their families. This study is also intended to test the training of community providers in the use of this model. Parents will receive coaching to provide interventions to support their child’s communication and other skills. You and your child may be eligible if your child is between 1 and 5 years old, your child is on a waitlist to be evaluated for ASD or has received an ASD diagnosis in the last 3 months & is waiting for services. Participants receive parent coaching 3x weekly for 9-12 weeks for 30-60 minutes over telehealth. Questionnaires and interviews are given before and after the intervention. Overall, parents commit to 18 months of participation.

Principal Investigator: Jessica Simacek
Age Group: 1 year and over
IRB Number: STUDY00022647
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 1 year and over
Inclusion Criteria:

• children 1 to 5 years old
• waiting for either Autism Spectrum Disorder (ASD) diagnosis or intervention
• at least one caregiver (approved by the parent) willing to participate
Exclusion Criteria:

• determined by study staff following review of child's specific behaviors
Conditions: Brain & Nervous System, Children's Health, Community Health
Keywords: Autism, Care Navigation, Caregiver Coaching, Children, Evaluation, Intervention, Telehealth, ASD

NEPTUNE: The Nephrotic Syndrome Study Network - RDCRN Protocol 6801 (NEPTUNE)

Nephrotic syndrome is a condition which affects the kidneys causing them to leak protein from the blood into the urine. Nephrotic syndrome is a disease that can improve (remission) and worsen (relapse) at different times throughout childhood. By collecting health information and laboratory samples, our goal is to learn more about these kidney diseases and find better ways to prevent and treat people with nephrotic syndrome. New knowledge will be shared with researchers and the public.

Principal Investigator: Patrick Nachman
Age Group: Not specified
This study is NOT accepting healthy volunteers
IRB Number: SITE00000599
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• Group A: up to 80 years of age with clinical diagnosis for FSGS/MCD or MN or pediatric participants who have protein in the urine and are scheduled for a kidney biopsy
• Group B: are less than 19 years old, have started immunosuppression drugs less than 30 days ago and have abnormal kidney lab values
Exclusion Criteria:

• prior solid organ transplant
• clinical diagnosis of glomerulopathy without diagnostic renal biopsy
• systemic lupus erythematosus (SLE)
• clinical evidence of other renal diseases
Conditions: Kidney, Prostate & Urinary
Keywords: Clinics and Surgery Center (CSC), Focal Segmental, Focal Segmental, Glomerulosclerosis, Glomerulosclerosis, Minimal Change Disease (MC
I'm interested
Share via email
See this study on ClinicalTrials.gov

Identifying Impairments in Bilateral Coordination in Individuals Post-Stroke

Bilateral coordination (ability to use both arms) is poorly understood in stroke. We are using a robotic device to measure bilateral coordination in different tasks in individuals with chronic stroke and people of the same age who have not had a stroke.

Principal Investigator: Rachel Hawe
Age Group: 18 years and over
This study is also accepting healthy volunteers
IRB Number: STUDY00019059
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is also accepting healthy volunteers
Inclusion Criteria:

• Chronic stroke diagnosed at least 6 months ago
• at least 45 years old
• experiencing one-sided weakness (Hemiparesis)
• Healthy Participants: at least 45 years old, no known orthopedic or musculoskeletal difficulties
Exclusion Criteria:

• medical diagnosis of any neurodegenerative disorder.
• unable to move the upper limbs
• unable to follow simple instructions
• any impairments or severe pain that limits the movement of the upper limb
Conditions: Brain & Nervous System
Keywords: Arm Movement, CVA, Rehabilitation, Robotics, Stroke
Visit study website
I'm interested
Share via email

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

We are looking at how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen made by the body and may stop the growth of tumor cells that need estrogen to grow. We will compare the effectiveness of the two different treatments.

Principal Investigator: Rahel Ghebre, Dr
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: MMCORC048
Show full eligibility criteria
Hide eligibility criteria
Sex: Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• newly diagnosed, stage II-IV low-grade serous ovarian cancer fallopian tube or primary peritoneal cancers
• surgery for maximal cytoreduction completed within 8 weeks of randomization
• bilateral salpingo-oophorectomy completed
• able to take oral medications
Exclusion Criteria:

• prior neoadjuvant chemotherapy, endocrine therapy or radiotherapy for the treatment of this disease
• severe cardiac disease
Conditions: Cancer
Keywords: Fallopian Tube cancer, Ovarian cancer, Peritoneal cancer, Serous carcinoma
I'm interested
Share via email
See this study on ClinicalTrials.gov

A Randomized Double Blind Phase II Trial of Restorative Microbiota Therapy (RMT) or Placebo in Combination with Durvalumab (MEDI4736) and Tremelimumab With Chemotherapy in Treatment Naïve Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer

The investigational therapy in this study is referred to as Restorative Microbiota Therapy (RMT). It is prepared by extracting healthy bacteria from the stool of healthy human donors and making it into capsules taken by mouth. The donor stool samples are rigorously tested for harmful bacteria and viruses before processing. There is scientific evidence to suggest that RMT might make immunotherapy more effective. The primary goal of the study is to test if RMT makes durvalumab + tremelimumab treatment with chemotherapy more effective to control lung cancer.

Principal Investigator: Manish Patel
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00007800
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• confirmed adenocarcinoma of the lung that is stage IIIB/C or stage IV that can't be surgically removed
• prior chemotherapy or immunotherapy as adjuvant therapy for lung cancer is permitted as long as it has been more than 6 months from last dose
• people who have treated brain metastasis are eligible as long as they have stable symptoms, are more than 2 weeks from completion of therapy, and do not require more than 10mg of daily prednisone or equivalent
• restricted in strenuous physical activity but can walk and carry out work of a light or sedentary nature, e.g., light house work, office work
• weigh at least 30 kg (66 lbs.)
• contact study staff for additional requirements
Exclusion Criteria:

• women who are pregnant or breast feeding
• unable to swallow medications
• additional medical and mental health diagnosis (study staff will review)
Conditions: Cancer, Respiratory System
Keywords: Clinics and Surgery Center (CSC), Adenocarcinoma of Lung, Lung Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov

STOP PEDS RCT (Streamlined Treatment of Pulmonary Exacerbations in Pediatrics Randomized Controlled Trial) (STOP PEDS RCT)

In this study, we are going to compare two ways of treating mild respiratory illnesses in children with Cystic Fibrosis (CF). One is immediate antibiotics (increase airway clearance and start oral antibiotics right away) and the other is tailored therapy (increase airway clearance right away but only start oral antibiotics if symptoms worsen or do not improve). We are looking at how safe each option is and how well each one works. To do this, we will randomize participants (like flipping a coin) to one of these two approaches if a mild respiratory illness happens over the next 12 months.

Principal Investigator: Samuel Goldfarb
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers
IRB Number: STUDY00023173
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• Age: for main study group and non-HEMT group: age 6 to less than 19 years old OR for preschool group: age 3 to less than 6 years old
• diagnosis of Cystic Fibrosis (CF)
• for main study group and non-highly effective modulator therapy (HEMT) group, able to do spirometry
• able to receive text messages and access the internet
• see link to clincialtrials.gov for complete inclusion criteria
Exclusion Criteria:

• history of solid organ transplant
• positive culture for Mycobacterium abscessus in the prior 12 months
• three or more IV antibiotic-treated pulmonary exacerbations (PEx) in the prior 12 months
• treatment with chronic oral antibiotics other than azithromycin at enrollment
• see link to clinicaltrials.gov for complete exclusion criteria
Conditions: Children's Health, Respiratory System
Keywords: CF, Cystic fibrosis
I'm interested
Share via email
See this study on ClinicalTrials.gov

Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis

This study is comparing the treatment of Non-Alcoholic Steatohepatitis (NASH) with either lifestyle changes or obesity surgery with lifestyle changes.  Participants must be 30-70 years old, have a BMI of 35.0-60.0 kg/m2, have health insurance that will pay for obesity surgery, and be willing to accept either treatment.

Principal Investigator: Sayeed Ikramuddin
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00014879
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• ages 30 to 70 years
• diagnosed with NASH with a total NAS >=4 including a ballooning score of at least 1, or diagnosed with T2DM or prediabetes, HbA1c < 9% Body Mass Index (BMI): 35.0-50.0 kg/m2
• willing to accept either surgery or life style changes
• must have insurance with no exclusion for obesity related treatments or management of obesity surgery complications. applies to all participants enrolled in the study
• evidence of liver fat present in the baseline MR images
• suitable for liver biopsy
Exclusion Criteria:

• cardiovascular event (myocardial infarction, acute coronary syndrome, coronary artery angioplasty or bypass, stroke) in the past six months
• pulmonary embolus or thrombophlebitis in the past six months
• cancer diagnosis unless disease free for five years
• alcohol intake more than one drink per day
• other physical or mental health disease (study staff will review)
Conditions: Digestive & Liver Health
Keywords: Bariatric Surgery, NASH, VSG, Clinics and Surgery Center (CSC), fatty liver, gastrectomy, sleeve, sleeve gastrectomy, weight loss
I'm interested
Share via email
See this study on ClinicalTrials.gov

Development and Validation of an MRI-Compatible Jaw Metabolic Stressor Task_Study1

The goal of this study is to develop and test a new way of measuring how much effort and strain the jaw muscles can handle before a person begins to feel specific levels of pain or fatigue. This involves a controlled jaw exercise task designed to better understand the relationship between jaw muscle effort, physical stress in the muscles, and how each person experiences discomfort. It is hoped that the information learned in this study will help researchers refine this new jaw testing method and confirm whether it accurately measures jaw muscle effort and discomfort. This may support future research that improves how jaw pain conditions are understood and eventually lead to better, more individualized treatments for people with jaw muscle and jaw joint disorders.

Principal Investigator: Estephan Moana-Filho
Age Group: 18 years and over
This study is also accepting healthy volunteers
IRB Number: STUDY00026440
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is also accepting healthy volunteers
Inclusion Criteria:

• Had a dental exam in the last year
• No significant body or mouth pain
Exclusion Criteria:

• Certain medical conditions (examples: autism, trigeminal neuralgia, pain conditions)
• Facial hair or significant skin darkening on the cheeks
Conditions: Dentistry
Keywords: Jaw function, JMS
I'm interested
Share via email

IMPACT: A Clinical Investigation on IMproving Peripheral Neuropathy Induced by Anti-Cancer Drugs with Advanced Compression Technology; A Safety and Efficacy Study (IMPACT)

The purpose of this study is to evaluate the effectiveness of investigational devices (the Lilac Glove and Lilac Boot devices) for the temporary reduction of moderate to severe symptoms of peripheral neuropathy caused by chemotherapy during the treatment of cancer. The Lilac Glove and Lilac Boot devices are designed to keep chemotherapy medication from damaging nerves. The study involves wearing the Lilac Glove and Boot devices on both hands and feet at each treatment session. Participants will be randomly assigned (like the flip of a coin) into one of two treatment groups; the “intervention group” (which means you receive treatment with the therapeutic Lilac devices) or the “control group” (which means you will receive treatment with the sham devices).

Principal Investigator: Melissa Geller, MD
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00027329
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• diagnosed solid tumor cancer, who will receive neo-adjuvant or adjuvant chemotherapy
• planned IV treatment with at least 4 cycles of chemotherapy, with no planned treatment pause for surgery
• willing to wear the Lilac Glove and Boot devices for the prescribed duration (devices to be fitted before infusion, and worn during infusion and for up to one (1) hours post infusion
• see link to clinicaltrials.gov for complete Inclusion criteria
Exclusion Criteria:

• baseline peripheral neuropathy of any kind
• chemotherapy in the previous 1 year
• any open wounds, sores, cysts or injury on the hands or on part of the upper arm where the device will be applied or on the feet or part of the lower leg where the device will be applied that may not be healed before chemotherapy starts
• untreated or uncontrolled hypertension
• poorly controlled diabetes
• weight greater than 140 kg (308 pounds)
• see link to clinicaltrials.gov for complete exclusion criteria
Conditions: Cancer
Keywords: Neuropathy, cancer, chemotherapy, Clinics and Surgery Center (CSC)
I'm interested
Share via email
See this study on ClinicalTrials.gov

MT2016-11 :Autologous Stem Cell Transplant In Patients with Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphomas (NHL)

The treatment (chemotherapy and transplant procedures) is considered standard clinical care that are usually given to the patients with this disease. The research aspect of this study is to collect data on the patients who are being treated on this plan. Patients will be followed throughout the course of their clinical care and for three years after their transplant.

Principal Investigator: Veronika Bachanova, MD
Age Group: Not specified
This study is NOT accepting healthy volunteers
IRB Number: 1611M99805
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• up to 75 years of age
• diagnosis of Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Mature B cell Lymphoma, or Mature T cell Lymphoma
• at least 4 weeks from previous chemotherapy; 6 weeks from nitrosoureas
• women of child bearing potential and sexually active males with partners of child bearing potential must agree to use adequate birth control for the duration of treatment
• see link to clinicaltrials.gov for complete criteria
Exclusion Criteria:

• women who are pregnant or breastfeeding
• chemotherapy resistant disease
• unrelated active infection
Conditions: Cancer
Keywords: Clinics and Surgery Center (CSC), Hodgkin Lymphoma, Non-Hodgkin Lymphoma
I'm interested
Share via email
See this study on ClinicalTrials.gov

AHOD2131, A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

This phase III trial studies brentuximab vedotin and combination chemotherapy to see how well they work compared to combination chemotherapy alone in treating children and young adults with stage IIB with bulk, stage IIIB, IVA, or IVB Hodgkin lymphoma. Combinations of biological substances in brentuximab vedotin may be able to carry cancer-killing substances directly to Hodgkin lymphoma cells. Chemotherapy drugs, such as doxorubicin hydrochloride, bleomycin sulfate, vincristine sulfate, etoposide, prednisone, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known if combination chemotherapy is more effective with or without brentuximab vedotin in treating children with high-risk Hodgkin lymphoma.

Principal Investigator: Peter Gordon
Age Group: Not specified
This study is NOT accepting healthy volunteers
IRB Number: SITE00001972
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 5 to 60 years old
• newly diagnosed untreated confirmed Hodgkin lymphoma
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Exclusion Criteria:

• patients with nodular lymphocyte predominant Hodgkin lymphoma
• patients with a history of active interstitial pneumonitis or interstitial lung disease
• administration of prior chemotherapy, radiation, or antibody-based treatment for classic Hodgkin Lymphoma (cHL)
• prior solid organ transplant
• prior allogeneic stem cell transplantation
• women who are pregnant or breast feeding
Conditions: Cancer
Keywords: cHL, Hodgkin Lymphoma, Hodgkin's, Lymphoma
I'm interested
Share via email
See this study on ClinicalTrials.gov

A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

This study is testing the study drug BDTX-4933 in people with locally advanced (unresectable) or metastatic solid tumors that are characterized by a KRAS, BRAF, or NRAS mutation/alteration(s). The primary objective of the study is to assess how well participants tolerate the drug and if it is effective.

Principal Investigator: Ajay Prakash
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00021016
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• recurrent or advanced (unresectable) or metastatic solid tumors or histiocytic neoplasms with documented RAS or BRAF mutations
• exhausted all available standard-of-care therapies
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Exclusion Criteria:

• cancer that has a known MEK1/2 mutation
• ongoing anticancer or radiation therapy
• women who are pregnant or breastfeeding
Conditions: Cancer
Keywords: Clinics and Surgery Center (CSC), metastatic cancer, RAS or BRAF mutations, Recurrent cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov

Solid Tumor Cancer Specimen Bank - Sarcoma Cohort

The purpose of this research is to collect, store and distribute specimens and information about people with solid tumors. Samples from many people are being collected and stored so they can be used for research now and in the future.

Principal Investigator: Naomi Fujioka
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00003639
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• diagnosis sarcoma
• planned visit at a University of Minnesota Cancer Clinic
Conditions: Cancer
Keywords: Clinics and Surgery Center (CSC)
I'm interested
Share via email

Using MRI Scans to Inform Individualized Neuromodulation Interventions in Major Depressive Disorders with and without Comorbidities

This study collects MRI brain scans before, during, and after treatment in people with depression and other mental health conditions who are receiving neuromodulation therapies. The goal is to see whether differences in brain structure can help explain why some people respond to treatment better than others.

Principal Investigator: Ziad Nahas
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00027225
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• age 18 or older
• seeking clinical or research neuromodulation interventions for depression (with or without comorbidities)
• able to read English
Exclusion Criteria:

• cannot complete MRI
Conditions: Mental Health & Addiction
Keywords: depression, MRI, neuromodulation
Visit study website
I'm interested
Share via email

Targeting Neuroplasticity for Persistent Post-Concussive Cognitive Symptoms: A Trial of tDCS and Cognitive Training 3-12 Months Post-mTBI

This study is looking at a new, non-invasive treatment approach for people who continue to have symptoms after a mild traumatic brain injury (such as a concussion). The treatment combines gentle brain stimulation with cognitive training exercises. The goal of the study is to see whether this combined approach can help improve thinking, memory, and overall daily functioning in individuals with persistent post-concussion symptoms. To see if you may be eligible, complete the screening form by selecting the "Visit the Study Website" button.

Principal Investigator: Kelvin Lim
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00026668
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• ages 18-65
• has sustained a single mTBI 3-12 months prior to enrollment
• meets criteria for persistent post-concussive syndrome
• reliable access to a smartphone
• see link to clinicaltrials.gov for complete Inclusion criteria
Exclusion Criteria:

• history of moderate/severe TBI
• significant neurological or psychiatric disorders (other than PPCS-related symptoms like mild depression/anxiety)
• contraindications to tDCS (e.g., implanted metal, skin lesions on scalp)
• see link to clinicaltrials.gov for complete Exclusion criteria
Conditions: Brain & Nervous System
Keywords: brain injury, brain stimulation, cognitive, concussion, mTBI, neuromodulation, TBI, tDCS

Extracellular Vesicles as Potential Biomarkers and Therapeutic Target in Gaucher Disease (Le-Na)

This is an observational study intended to generate preliminary data to understand how lysosomal dysfunction can affect the biogenesis of extracellular vesicles, its content and function. The study entails 2 visits over a 3-month period. On enrollment, participants will be scheduled for the 2 visits, during which fasting blood samples will be collected.

Principal Investigator: Reena Kartha
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00013672
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• ages 18 to 80
• diagnosis of Gaucher Disease
Exclusion Criteria:

• hematological cancer or other uncontrolled medical conditions
Conditions: Rare Diseases
Keywords: Gaucher Disease
I'm interested
Share via email
See this study on ClinicalTrials.gov

A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003) (OMAHA-003)

This trial is testing MK-5684 in men with metastatic castration-resistant prostate cancer (mCRPC) previously treated with next-generation Hormonal Agent (NHA) and Taxane-based chemotherapy. This trial will compare MK-5684 to abiraterone acetate and enzalutamide. Abiraterone acetate and enzalutamide are standard treatments for mCRPC. The purpose of this trial is to test the safety of the trial drug, MK-5684, see how well the drug works, and see how the body handles the drug. We also want to see if participants who get MK-5684 live longer compared to those who get abiraterone acetate or enzalutamide.

Principal Investigator: Emmanuel Antonarakis
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00021305
Show full eligibility criteria
Hide eligibility criteria
Sex: Male
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• diagnosis of adenocarcinoma of the prostate
• cancer progression while on androgen deprivation therapy with metastasis to bone or other areas of the body
• received 1 but no more than 2 taxane-based chemotherapy regimens
• unable to do strenuous activity but walking and able to carry out work of a light or sedentary nature, e.g., light house work, office work
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Exclusion Criteria:

• unable to swallow capsules/tablets
• gastrointestinal disorder that might affect absorption
• poorly controlled diabetes mellitus
• history of clinically significant ventricular arrhythmias
• known additional cancer that is progressing or has required active treatment within the past 3 years
Conditions: Cancer
Keywords: Clinics and Surgery Center (CSC), mCRPC, metastatic castration-resistant prostate cancer, Prostate Cancer Metastatic
I'm interested
Share via email
See this study on ClinicalTrials.gov

The effects of vagus nerve stimulation on intrinsic lower leg spinal motoneuron excitability in Parkinson's disease

This study is designed to better understand the mechanisms contributing to impaired activation of leg muscles in people with Parkinson’s disease (PD) and test if stimulation of a nerve at the neck (vagus nerve) can improve muscle activation, walking and balance. People can participate in one of two experiments, or both. Both experiments will test the muscle activation patterns in the lower leg when producing low levels of force. We will also assess walking and balance. Experiment 2 will test muscle activation patterns, walking and balance before and after vagus nerve stimulation. We are also asking people who don’t have PD and are 21 to 76 years old and match in age and sex to participants to undergo the same study procedures.

Principal Investigator: Colum MacKinnon
Age Group: 18 years and over
This study is also accepting healthy volunteers
IRB Number: STUDY00026350
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is also accepting healthy volunteers
Inclusion Criteria:
We are looking for people with Parkinson's Disease who have a diagnosis of PD and are between 21-76 years old. Participants must be able to walk without the use of an assistive device for more than 50 meters (164 feet). They must also be on stable medication for the preceding month and anticipated over the next 3 months.
Healthy volunteers
must be between 40-76 years old who will then be age matched to people in the study who have Parkinson's Disease.
• See link to clinicaltrials.gov for complete Inclusion criteria
Exclusion Criteria:

• history of another significant neurological disorder including stroke, traumatic brain injury, intracranial aneurysm, intracranial hemorrhage, brain tumor
• severe orthopedic or other related musculoskeletal disease that significantly affects gait
• women who are pregnant
• history of substance abuse in the past two years
• unable to comprehend English
• see link to clinicaltrials.gov for complete Exclusion criteria
Conditions: Brain & Nervous System
Keywords: Clinics and Surgery Center (CSC), Parkinson's Disease PD
I'm interested
Share via email
See this study on ClinicalTrials.gov

Transcranial Magnetic Stimulation to Augment Behavior Therapy for Tics: R33 Phase

This study will look at the effects of treatment combining Comprehensive Behavioral Intervention for Tics (CBIT) and Transcranial Magnetic Stimulation (TMS) for young people who have tic disorder. Participants must be 12- 21 years old and able to have an MRI. All participants will receive 10 daily sessions of CBIT, a well-established behavioral treatment that is considered to be the first treatment for tics. Participants will also be assigned randomly (by chance) to receive TMS or a sham (treatment not delivered) just before each CBIT session. The device for TMS delivers electromagnetic stimulation to a specific area of the brain with a small coil on the scalp. The effectiveness of the CBIT for the two groups, with and without the TMS, will be compared.

Principal Investigator: Christine Conelea
Age Group: 12 years to 21 years old
This study is NOT accepting healthy volunteers
IRB Number: STUDY00023755
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 12 years to 21 years old
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• between the ages of 12 – 21
• currently experiencing chronic motor and/or vocal tics
• able to undergo MRI
• study staff will review additional exclusion criteria
Exclusion Criteria:

• currently receiving therapy focused on tics
• currently taking neuroleptic/antipsychotic medications
Conditions: Brain & Nervous System, Children's Health, Mental Health & Addiction
Keywords: TMS, Tourette's syndrome, Vocal tics, CBIT, Motor tics, Tic Disorder
I'm interested
Share via email
See this study on ClinicalTrials.gov

Investigating Vaped Phenanthrene Biomarkers in Former Smokers

Former smokers continue to be at higher risk for developing lung cancer than non-smokers,even years after quitting. This study will look at how a specific chemical, phenanthrene, is broken down in the lungs of former smokers and non-smokers. If former smokers break down chemicals in a more harmful way, it might help explain their increased risk for lung cancer. Study participants will be asked to attend an in-person study visit to vape a small amount of phenanthrene and then collect their urine for 24 hours afterwards.

Principal Investigator: Stephen Hecht, PhD
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00017204
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• In good health
• 21 years or older
• Previously smoked cigarettes daily for at least 10 years
• Have been completely quit for at least 1 year
• Have tried vaping at least once
• Willing to vape a study compound (does not contain nicotine)
Exclusion Criteria:

• Current smoker
Conditions: Prevention & Wellness
Keywords: cigarettes, former smokers, non-smoker, previous smokers, smoked, tobacco, vape, vaped, vaping
I'm interested
Share via email